Valuation: TTY Biopharm Company Limited

Market Cap 19.89B 611M 545M 500M 455M 853M 57.81B 870M 5.97B 2.41B 30.51B 2.29B 2.24B 96.37B P/E 2024 *
-
P/E 2025 -
Enterprise Value 19.89B 611M 545M 500M 455M 853M 57.81B 870M 5.97B 2.41B 30.51B 2.29B 2.24B 96.37B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
78.69%
Yield 2024 *
-
Yield 2025 -
1 day+0.13%
1 week-0.74%
Current month+0.13%
1 month+1.39%
3 months+7.53%
6 months+7.82%
Current year-1.84%
1 week 79.7
Extreme 79.7
81
1 month 78.2
Extreme 78.2
83.8
Current year 71.6
Extreme 71.6
87
1 year 71.6
Extreme 71.6
87
3 years 66.2
Extreme 66.2
87
5 years 66.2
Extreme 66.2
88.5
10 years 54.2
Extreme 54.2
120.5
Manager TitleAgeSince
Chief Executive Officer - 18/04/2022
Director of Finance/CFO - 31/12/2015
Compliance Officer - 18/04/2022
Director TitleAgeSince
Director/Board Member - 24/07/1995
Director/Board Member - 24/06/2016
Director/Board Member 70 24/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
+0.13%-0.74%+0.63%-4.53% 611M
-0.46%+10.31%+63.52%+143.15% 1,257B
-0.97%+1.60%+43.25%+80.09% 651B
-2.05%+0.73%+32.47%+101.62% 510B
-1.54%+0.18%+53.42%+66.79% 388B
-0.78%+5.51%+72.55%+44.25% 366B
-1.69%+3.17%+32.49%+55.35% 303B
-0.72%+7.83%+11.15%+33.76% 288B
-0.12%+4.68%+55.97%+74.59% 252B
-0.21%+7.34%+42.19%+109.69% 211B
Average -0.77%+4.06%+40.76%+70.47% 422.73B
Weighted average by Cap. -0.73%+5.30%+49.18%+93.32%

Financials

2024 2025
Net sales 5.89B 181M 162M 148M 135M 253M 17.13B 258M 1.77B 714M 9.04B 679M 665M 28.55B 6.45B 198M 177M 162M 148M 277M 18.75B 282M 1.94B 781M 9.9B 743M 728M 31.26B
Net income 1.45B 44.5M 39.73M 36.46M 33.16M 62.17M 4.21B 63.41M 435M 176M 2.22B 167M 163M 7.02B 1.56B 47.86M 42.73M 39.21M 35.67M 66.87M 4.53B 68.2M 468M 189M 2.39B 180M 176M 7.55B
Net Debt - -
Projected Income Statement - Annual - TTY Biopharm Company Limited
Logo TTY Biopharm Company Limited
TTY Biopharm Co Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of pharmaceutical preparations. The Company mainly operates through six business segments including Cancer Drug segment, Healthcare segment, Anti-Infective Drug segment, Domestic Cardiovascular and Gastrointestinal Drug segment, Mainland Medical Drug segment and the Other segment. The main products include oncology medicines, anti-infective medicines and health care medicines. Oncology medicines are mainly anti-cancer and auxiliary drugs. Anti-infective medicines are mainly back-line antimicrobial agents and influenza vaccines. Medical and health care medicines are mainly gastrointestinal health care, bone health care, metabolic health care, infection treatment drugs. The Company distributes its products in domestic and overseas markets.
Employees
-
Date Price Change Volume
02/11/26 NT$80.00 +0.13% 362,534
30/10/26 NT$79.90 -0.62% 807,595
29/10/26 NT$80.40 +0.37% 440,848
28/10/26 NT$80.10 -0.62% 625,548
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - TTY Biopharm Company Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
80.00TWD
Average target price
92.00TWD
Spread / Average Target
+15.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - TTY Biopharm Company Limited
  1. Stock Market
  2. Stocks
  3. 4105 Stock